Brokerages expect that Sage Therapeutics, Inc. (NASDAQ:SAGE) will announce earnings of ($1.66) per share for the current quarter, Zacks reports. Zero analysts have made estimates for Sage Therapeutics’ earnings, with the lowest EPS estimate coming in at ($2.00) and the highest estimate coming in at ($1.50). Sage Therapeutics posted earnings of ($1.08) per share in the same quarter last year, which suggests a negative year over year growth rate of 53.7%. The business is scheduled to report its next quarterly earnings results on Tuesday, August 8th.

According to Zacks, analysts expect that Sage Therapeutics will report full-year earnings of ($6.70) per share for the current fiscal year, with EPS estimates ranging from ($8.32) to ($5.90). For the next fiscal year, analysts forecast that the business will report earnings of ($5.72) per share, with EPS estimates ranging from ($6.80) to ($4.26). Zacks Investment Research’s earnings per share averages are an average based on a survey of sell-side analysts that cover Sage Therapeutics.

Sage Therapeutics (NASDAQ:SAGE) last announced its earnings results on Tuesday, May 9th. The biopharmaceutical company reported ($1.52) EPS for the quarter, beating analysts’ consensus estimates of ($1.61) by $0.09.

A number of equities research analysts recently issued reports on SAGE shares. Canaccord Genuity reissued a “buy” rating and set a $110.00 price target on shares of Sage Therapeutics in a research note on Tuesday, March 21st. J P Morgan Chase & Co reissued a “buy” rating and set a $83.00 price target on shares of Sage Therapeutics in a research note on Monday, April 3rd. Bank of America Corporation started coverage on Sage Therapeutics in a research note on Friday, May 12th. They set a “buy” rating and a $85.00 price target for the company. Needham & Company LLC started coverage on Sage Therapeutics in a research note on Monday, May 15th. They set a “buy” rating and a $82.00 price target for the company. Finally, ValuEngine raised Sage Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, June 2nd. Four investment analysts have rated the stock with a hold rating, nine have given a buy rating and two have issued a strong buy rating to the company. The company presently has an average rating of “Buy” and an average target price of $85.82.

Large investors have recently modified their holdings of the stock. Emerald Mutual Fund Advisers Trust purchased a new stake in shares of Sage Therapeutics during the first quarter worth $7,139,000. Essex Investment Management Co. LLC raised its stake in shares of Sage Therapeutics by 164.6% in the first quarter. Essex Investment Management Co. LLC now owns 30,873 shares of the biopharmaceutical company’s stock worth $2,194,000 after buying an additional 19,204 shares during the period. Russell Investments Group Ltd. raised its stake in shares of Sage Therapeutics by 82.1% in the first quarter. Russell Investments Group Ltd. now owns 19,679 shares of the biopharmaceutical company’s stock worth $1,399,000 after buying an additional 8,872 shares during the period. Janney Montgomery Scott LLC purchased a new stake in shares of Sage Therapeutics during the first quarter worth $256,000. Finally, Candriam Luxembourg S.C.A. raised its stake in shares of Sage Therapeutics by 128.1% in the first quarter. Candriam Luxembourg S.C.A. now owns 73,000 shares of the biopharmaceutical company’s stock worth $5,188,000 after buying an additional 41,000 shares during the period.

ILLEGAL ACTIVITY NOTICE: This piece was posted by American Banking News and is owned by of American Banking News. If you are reading this piece on another site, it was stolen and reposted in violation of U.S. and international copyright & trademark legislation. The legal version of this piece can be read at https://www.americanbankingnews.com/2017/07/19/1-66-earnings-per-share-expected-for-sage-therapeutics-inc-sage-this-quarter.html.

Sage Therapeutics (SAGE) opened at 81.69 on Wednesday. Sage Therapeutics has a one year low of $35.02 and a one year high of $88.93. The company’s 50 day moving average price is $77.73 and its 200-day moving average price is $66.73. The company’s market cap is $3.05 billion.

Sage Therapeutics Company Profile

SAGE Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. The Company’s lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the Gamma-Amino Butyric Acid-A (GABAA) receptor.

Get a free copy of the Zacks research report on Sage Therapeutics (SAGE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Sage Therapeutics (NASDAQ:SAGE)

Receive News & Ratings for Sage Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sage Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.